PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34494163-0	2022	Correction to: Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.	esaxerenone	126-137	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102	
34415382-0	2022	Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.	esaxerenone	111-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-87	
34415382-2	2022	Physiologically based pharmacokinetic (PBPK) modelling was performed to predict the drug-drug interaction (DDI) effect of cytochrome P450 (CYP)3A modulators on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.	esaxerenone	160-171	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-145	
34415382-3	2022	METHODS: In our PBPK model, the fraction of esaxerenone metabolised by CYP3A was estimated from mass-balance data and verified and optimised by clinical DDI study results with strong CYP3A modulators.	esaxerenone	44-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-76	
34415382-3	2022	METHODS: In our PBPK model, the fraction of esaxerenone metabolised by CYP3A was estimated from mass-balance data and verified and optimised by clinical DDI study results with strong CYP3A modulators.	esaxerenone	44-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	183-188	
34415382-5	2022	The model was applied to predict the DDI effects on esaxerenone pharmacokinetics with untested CYP3A modulators in healthy subjects and with strong CYP3A modulators in subjects with hepatic impairment.	esaxerenone	52-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-100	
34415382-5	2022	The model was applied to predict the DDI effects on esaxerenone pharmacokinetics with untested CYP3A modulators in healthy subjects and with strong CYP3A modulators in subjects with hepatic impairment.	esaxerenone	52-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-153	
34383278-1	2021	BACKGROUND AND OBJECTIVE: Esaxerenone showed the potential to inhibit and induce activity against cytochrome P450 (CYP) 3A in in vitro studies.	esaxerenone	26-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-122	
34383278-12	2021	Esaxerenone can be concomitantly administered with drugs of CYP3A substrates without dose adjustments.	esaxerenone	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-65	
32250463-12	2020	These results suggest that caution is recommended when coadministering esaxerenone with strong inhibitors and inducers of CYP3A.	esaxerenone	71-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-127	
30541878-8	2019	In vitro studies showed that esaxerenone was a substrate of CYP3A and multiple UDP-glucuronosyltransferase isoforms.	esaxerenone	29-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-65	
32616542-3	2020	Esaxerenone exhibited time-dependent inhibition and induction of cytochrome P450 3A (CYP3A).	esaxerenone	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-83	
32616542-3	2020	Esaxerenone exhibited time-dependent inhibition and induction of cytochrome P450 3A (CYP3A).	esaxerenone	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-90	
32616542-4	2020	When the clinical impacts of esaxerenone on the inhibition and induction of CYP3A were estimated separately by using a mechanistic static model, the predicted area under the curve ratios (AUCRs) of midazolam, a typical CYP3A substrate, were 1.89 and 0.33, respectively.	esaxerenone	29-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-81	
32616542-4	2020	When the clinical impacts of esaxerenone on the inhibition and induction of CYP3A were estimated separately by using a mechanistic static model, the predicted area under the curve ratios (AUCRs) of midazolam, a typical CYP3A substrate, were 1.89 and 0.33, respectively.	esaxerenone	29-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	219-224